ABSTRACT
Objective To investigate the action of ulinastatin in protection of hepatic-renal function in patients with acute myocardial infarction (AMI) receiving emergency percutaneous coronary intervention (PCI). Methods 104 patients with acute myocardial infarction were randomly selected and divided into a study group (n = 55) and a control group (n = 49). The study group received intravenous ulinastatin of 300,000 units one hour before PCI, and 300,000 units daily for 3 days after the procedure; while the control group received the same amount of normal saline instead of ulinastatin before and after PCI. Levels of AST, ALT, and CRE were compared between the two groups and CCR was counted before and 72 hours after the procedure. Result Serum AST level was increased and CCR was decreased after PCI; and the change in the study group was lower than that in the control group (P < 0.05). ALT level was declined in the study group but was elevated in the control group after the procedure, with a significant difference between the two groups (P < 0.05). Conclusions Ulinastatin can protect hepatic-renal function in patients undergoing emergency PCI, lowering contrast-induced nephropathy and damage of liver and kidneys.